Introducing Once-Daily Dosing for Diabetic Dogs with PROZINC® (protamine zinc recombinant human insulin)

Duluth, Georgia – August 26, 2020 – Today, Boehringer Ingelheim unveiled a new presentation of PROZINC® (protamine zinc recombinant human insulin) with the proven benefit of once-daily dosing in most canine diabetic patients¹. Now, with two presentations designed for feline and canine patients, PROZINC is the insulin veterinarians have been waiting for.

“Once-daily dosing with PROZINC is a breakthrough for pet owners with diabetic dogs,” explained Grant Beckett, BVSc MRCVS, senior associate director, Technical Marketing, Boehringer Ingelheim Animal Health. “A single injection can provide consistent and reliable control of clinical signs for 18 to >24 hours in most canine patients¹. Not only is PROZINC more convenient for dog owners, but it reinforces veterinarians’ commitment to providing a better quality of life for their patients.”

PROZINC is FDA-approved to reduce hyperglycemia and hyperglycemia-associated clinical signs in dogs², and offers:

• An extended duration of action: pharmacokinetic/pharmacodynamic data demonstrate a duration of action, in both healthy and diabetic dogs, of 16 to >24 hours with once-daily, single site administration of protamine zinc recombinant human insulin^1,2
• Consistent glycemic control: based on a study using continuous glucose monitoring, there was low intra-day variability of blood glucose levels in dogs that were well regulated on PROZINC¹
• Demonstrated improvement in clinical signs: in a field study, clinical signs, including polydipsia, polyuria, and weight loss, began to ameliorate quickly, and then progressively
  • 62% of dogs showed improvement by Day 14, and 87% of dogs showed improvement by Day 84²
• Rigorously tested efficacy: diabetic control with PROZINC was attained at similar rates in both naïve and previously-treated populations²

To assist pet owners with at-home care, Boehringer Ingelheim offers tools and education – including a home care diary, dosing magnets and digital education materials, available at PROZINC.US. “With our materials, diabetic dogs and their owners will be equipped to lead happier lives,” added Beckett.

IMPORTANT SAFETY INFORMATION: PROZINC is for use in dogs and cats only. Keep out of the reach of children. Animals presenting with severe ketoacidosis, anorexia, lethargy, and/or vomiting should be stabilized with short-acting insulin and appropriate supportive therapy until their condition is stabilized. As with all insulin products, careful patient monitoring for hypoglycemia and hyperglycemia is essential to attain and maintain adequate glycemic control and to prevent associated complications. Overdose can result in profound hypoglycemia and death. The most common adverse reactions were lethargy, anorexia, hypoglycemia, vomiting, seizures, shaking (dogs only), diarrhea, and ataxia. Many of the adverse reactions, such as lethargy, seizures, shaking (dogs only), and ataxia, are associated with hypoglycemia. Glucocorticoid and progestogen use should be avoided. The safety and effectiveness of PROZINC in puppies, kittens, or breeding, pregnant, and lactating animals has not been evaluated. PROZINC is contraindicated during episodes of hypoglycemia and in animals sensitive to protamine zinc recombinant human insulin or any other ingredients in PROZINC. For more information, please see full prescribing information.

Boehringer Ingelheim Animal Health
The lives of animals and humans are interconnected in deep and complex ways. We know that when animals are healthy, humans are healthier too. Across the globe, our 10,000 employees are dedicated to delivering value through innovation, thus enhancing the well-being of both.Respect for animals, humans and the environment is at the heart of what we do. We develop solutions and provide services to protect animals from disease and pain. We support our customers in taking care of the health of their animals and protect our communities against life- and societythreatening diseases.

Boehringer Ingelheim Animal Health is the second largest animal health business in the world, with net sales of $4.5 billion (4 billion euros) in 2019 and presence in more than 150 countries.

Boehringer Ingelheim Animal Health has a significant presence in the United States, with more than 3,100 employees in places that include Georgia, Missouri, Iowa, Minnesota, New Jersey and Puerto Rico. To learn more, visit www.boehringer-ingelheim.us, www.facebook.com/BoehringerAHUS or www.twitter.com/Boehringer_AH.

Media Contacts
Ginny Dunn
Boehringer Ingelheim
Ginny.dunn@boehringer-ingelheim.com

Tom Mentzer
Mentzer PR Group (for PROZINC)
tmentzer@mprg.biz
913.626.9066

References

¹Data on file at Boehringer Ingelheim

²ProZinc® (protamine zinc recombinant human insulin) [Freedom of Information Summary]. Duluth, GA: Boehringer Ingelheim Animal Health USA Inc. ; 2019.

PROZINC® is a registered trademark of Boehringer Ingelheim Animal Heath USA Inc. ©2020 Boehringer Ingelheim Animal Health USA Inc. Duluth, GA. All rights reserved. US-PET-0551-2020